Please provide your email address to receive an email when new articles are posted on . The combination of amivantamab-vmjw and lazertinib extended OS by more than 1 year. Previously reported results ...
The most common combination regimen was MTX plus a TNF inhibitor, followed by MTX plus an IL-23 inhibitor and then MTX plus an IL-17 inhibitor. A total of 7230 AEs were reported, including 680 SAEs (9 ...
Treatment with MTX plus TNF, IL-23, or IL-17 inhibitors was associated with an increase in gastrointestinal AEs, although this finding was statistically significant only among patients receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback